BD (Becton, Dickinson and Company) announced its board of directors has approved the planned spinoff of its diabetes care business, which will be known as Embecta Corp ("embecta").
The board voted unanimously to approve the spinoff to occur on April 1, 2022, concluding that the separation of the diabetes care business from the rest of BD is consistent with BD's growth strategy and helps to sharpen its focus on its core innovation priorities.
